Quanterix Introduces New Dried Blood Spot Extraction Kit for Ultrasensitive Biomarker Detection
Quanterix Corporation, a pioneering biotech company based in Billerica, Massachusetts, announced an exciting new addition to their comprehensive line of Simoa® assay kits at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Vienna, Austria. This new development is a game-changer for researchers in the field of biomarker detection, particularly those investigating low-concentration biomarkers in Alzheimer’s and Parkinson’s diseases.
What is the New Dried Blood Spot Extraction Kit?
The new dried blood spot (DBS) extraction kit allows researchers to extract and measure biomarkers directly from DBS samples. This method offers several advantages over traditional liquid biopsies, such as ease of sample collection, storage, and transport. DBS samples require only a few microliters of whole blood, making them an ideal choice for large-scale population studies.
How Will This Impact Researchers?
With the new Quanterix DBS extraction kit, researchers will be able to detect biomarkers at ultrasensitive levels, enabling them to identify subtle changes in biomarker concentrations that may be indicative of disease progression or response to therapeutic interventions. This level of sensitivity is crucial for advancing our understanding of complex neurological disorders like Alzheimer’s and Parkinson’s diseases.
Global Implications
The introduction of this new Quanterix DBS extraction kit has far-reaching implications for the scientific community. By providing researchers with a more accessible, cost-effective, and user-friendly method for biomarker detection, this technology has the potential to accelerate the pace of scientific discovery and ultimately lead to the development of more effective therapeutic interventions for neurological disorders. Furthermore, the ease of sample collection and storage offered by DBS samples makes population studies more feasible, paving the way for large-scale epidemiological research.
Conclusion
Quanterix Corporation’s new DBS extraction kit is a significant step forward in the quest for ultrasensitive biomarker detection. This innovative technology offers numerous advantages for researchers, including ease of sample collection, storage, and transport, as well as the ability to detect biomarkers at unprecedented levels of sensitivity. With this new tool in their arsenal, researchers will be better equipped to unravel the mysteries of complex neurological disorders like Alzheimer’s and Parkinson’s diseases. Ultimately, this technology has the potential to revolutionize the way we approach biomarker research and pave the way for the development of more effective therapeutic interventions.
- Quanterix Corporation introduces new DBS extraction kit for Simoa® assay kits at AD/PD conference
- New kit enables ultrasensitive biomarker detection from DBS samples
- Advantages include ease of sample collection, storage, and transport
- Implications for researchers: Improved sensitivity for disease progression and response to therapeutics
- Global implications: Accelerated pace of scientific discovery and large-scale population studies
